scholarly journals The projected economic and health burden of uncontrolled asthma in the United States

2019 ◽  
Author(s):  
Mohsen Yaghoubi ◽  
Amin Adibi ◽  
Abdollah Safari ◽  
J Mark FitzGerald ◽  
Mohsen Sadatsafavi ◽  
...  
Keyword(s):  
United States ◽  
Asthma Control ◽  
Economic Burden ◽  
Indirect Costs ◽  
State Level ◽  
The United States ◽  
Suboptimal Control ◽  
Asthma Prevalence ◽  
Uncontrolled Asthma ◽  
Life Years

AbstractRationaleDespite effective treatments, a large proportion of asthma patients do not achieve sustained asthma control. The ‘preventable’ burden associated with lack of proper control is likely taking a high toll at the population level.ObjectiveWe predicted the future health and economic burden of uncontrolled asthma among American adults for the next 20 years.MethodsWe built a probabilistic model that linked state-specific estimates of population growth, asthma prevalence rates, and distribution of asthma control levels. We conducted several meta-analyses to estimate the adjusted differences in healthcare resource use, quality-adjusted life years (QALYs), and productivity loss across control levels. We projected, nationally and at the state-level, total direct and indirect costs (in 2018 USD) and QALYs lost due to uncontrolled asthma from 2019 to 2038 in the United States.Measurements and Main ResultsOver the next 20 years, the total undiscounted direct costs associated with suboptimal asthma control will be $300.6 billion (95% confidence interval [CI] $190.1 – $411.1). When indirect costs are added, total economic burden will be $963.5 billion (95%CI $664.1 – $1,262.9). American adolescents and adults will lose 15.46 million (95%CI 12.77 million – 18.14 million) QALYs over this period due to suboptimal control of asthma. In state-level analysis, the average 20-year per-capita costs due to uncontrolled asthma ranged from $2,209 (Arkansas) to $6,132 (Connecticut).ConclusionThe burden of uncontrolled asthma will continue to grow for the next twenty years. Strategies towards better management of asthma may be associated with substantial return on investment.

scholarly journals Economic Burden of Periodontal Disease in Europe and the United States of America – An updated forecast

2021 ◽  
Author(s):  
João Botelho ◽  
Luís Proença ◽  
Yago Leira ◽  
Leandro Chambrone ◽  
José João Mendes ◽  
...  
Keyword(s):  
United States ◽  
Periodontal Disease ◽  
Economic Burden ◽  
United States Of America ◽  
Periodontal Diseases ◽  
Indirect Costs ◽  
The United States ◽  
European Countries ◽  
Life Years ◽  
The Usa

AbstractIntroductionPeriodontal disease is a pandemic condition and its severe form affects approximately 10% of the global population. Here, we present a forecast for the economic burden of periodontal disease in 32 European countries and in the United States of America (USA).Material and methodsIn an aggregate population-based cost analysis, taken as reference the most recent available data, we estimated the cost of periodontal disease. Under this, global health, dental and periodontal expenditures were estimated. Additionally, indirect estimates accounted for Disability-Adjusted Life Years (DALY) valued at per capita Gross Domestic Product (GDP), to estimate productivity losses, including periodontal disease, edentulism due to periodontal disease and caries due to periodontal disease.ResultsIn 2018 the aggregate cost in Europe was estimated at €17.00B and €2.35B more in the USA (€19.35B). Indirect costs due to periodontal disease amounted to €132.52B in European countries and €103.30B in the USA. The majority of the projected indirect costs were due to edentulism related to periodontal disease and periodontal disease. Indirect costs were the major portion of the estimated economic impact with an average of 0.66% of GDP in Europe and 0.50% in the USA. For the overall costs (direct and indirect), the value amounted to 0.75% of GDP in Europe and 0.60% in the USA.ConclusionPeriodontal disease caused a €149.52B loss in Europe and €122.65B in the USA, in 2018. These results show that the economic burden of periodontal disease is increasing.CLINICAL RELEVANCEScientific rationale for the studyConsidering the pandemic pattern of periodontal diseases we present a forecast for the economic burden of periodontal disease in 32 European countries and in the United States of America (USA).Principal findingsPeriodontal disease caused a €149.52B loss in Europe and €122.65B in the USA, in 2018. For the overall costs (direct and indirect), the value amounted to 0.75% of GDP in Europe and 0.60% in the USA.Practical implicationsThese results show that the economic burden of periodontal disease is increasing.

The Economic Burden of Cancer in the United States

2017 ◽  
Author(s):  
K. Robin Yabroff ◽  
Gery P. Guy ◽  
Matthew P. Banegas ◽  
Donatus U. Ekwueme
Keyword(s):  
United States ◽  
End Of Life ◽  
Economic Burden ◽  
Initial Period ◽  
Indirect Costs ◽  
The United States ◽  
Use Of Resources ◽  
Initial Care ◽  
Pain And Suffering ◽  
Care Costs

With an aging and growing population and improved early detection and survival following diagnosis in the United States, the number of cancer survivors and prevalence of survivorship are expected to increase. Based on population trends, national expenditures for cancer care are projected to increase from $124.6 billion in 2010 to $157.8 billion in 2020. This chapter describes the economic burden of cancer, including direct costs, resulting from the use of resources for medical care for cancer; indirect costs, resulting from the loss of economic resources and opportunities associated with morbidity and mortality due to cancer and its treatment; and psychosocial or intangible costs, such as pain and suffering. Consistent with the intensity of treatment for initial care, recurrence, and end-of-life care, costs are highest in the initial period following diagnosis and, among patients who die from their disease, at the end of life, following a U-shaped curve.

Estimated Prevalence and Economic Burden of Severe, Uncontrolled Asthma in the United States

2013 ◽  
Vol 131 (2) ◽  
pp. AB126 ◽  
Author(s):  
Cheryl S. Hankin ◽  
Amy Bronstone ◽  
Zhaohui Wang ◽  
Mary Buatti Small ◽  
Philip Buck
Keyword(s):  
United States ◽  
Economic Burden ◽  
The United States ◽  
Uncontrolled Asthma

HSR19-102: Direct and Indirect Economic Burden of Cervical Cancer (CxCa) in the United States in 2015: A Mixed-Methods Analysis

2019 ◽  
Vol 17 (3.5) ◽  
pp. HSR19-102
Author(s):  
Chizoba Nwankwo ◽  
Shelby L. Corman ◽  
Ruchit Shah ◽  
Youngmin Kwon
Keyword(s):  
United States ◽  
Mixed Methods ◽  
Economic Burden ◽  
Healthcare Costs ◽  
Indirect Costs ◽  
Early Death ◽  
The United States ◽  
Productivity Costs ◽  
Direct And Indirect Costs ◽  
Lost Productivity

Background: An estimated 12,820 women in the United States will be diagnosed with CxCa in 2018, with 4,210 deaths from the disease. The economic burden of CxCa, both in terms of healthcare costs and lost productivity, has not been adequately studied. Methods: This was a mixed-methods study that evaluated the direct and indirect costs of CxCa using data from the Medical Expenditure Panel Survey (MEPS) for prevalent CxCa cases and the National Center for Health Statistics (NCHS) for deaths due to CxCa. Total healthcare costs and number of work days missed were compared between CxCa cases and controls in MEPS, using propensity scores calculated from baseline demographics and comorbidities. Missed work was converted to costs using the average hourly wage for women in 2015. Per-patient incremental healthcare and lost work productivity costs were then multiplied by the number of prevalent cases of CxCa in 2015 obtained from the Surveillance, Epidemiology, and End Results Program (SEER). NCHS data on the age-stratified number of CxCa deaths per year (1935–2015) and life expectancy data from the Social Security Administration were then used to calcluate the number of women who would be alive in 2015 if they had not died from CxCa and the lost earnings resulting from early mortality. The primary study outcome was the total direct and indirect cost of CxCa in 2015, calculated as the sum of the incremental direct healthcare costs, incremental lost productivity costs due to missed work, and lost productivity costs resulting from early death due to CxCa. Results: An estimated 257,524 women were alive with CxCa in 2015. Total healthcare costs were $4,221 higher, and an additional 0.37 work days were missed in women with CxCa compared to propensity-matched controls. Of the 488,475 women who died of CxCa prior to 2015, 108,832 would be alive in 2015 and 38,540 would be part of the workforce. Lost earnings in 2015 attributable to these deaths totaled $2.19 billion. The total economic burden of CxCa in the United States in 2015 was thus estimated at $3.3 billion (Table 1). Conclusions: CxCa was responsible for nearly $3.3 billion in direct and indirect costs in 2015. Early death among women with CxCa was the biggest driver of total economic burden.

scholarly journals Economic Burden among Commercially Insured Patients with Systemic Sclerosis in the United States

2019 ◽  
Vol 46 (8) ◽  
pp. 920-927 ◽  
Author(s):  
Zhou Zhou ◽  
Yanni Fan ◽  
Wenxi Tang ◽  
Xinyue Liu ◽  
Darren Thomason ◽  
...  
Keyword(s):  
United States ◽  
Systemic Sclerosis ◽  
Economic Burden ◽  
Index Date ◽  
Indirect Costs ◽  
The United States ◽  
Healthcare Resource Utilization ◽  
Work Loss ◽  
Signed Rank ◽  
Rate Ratios

Objective.To quantify healthcare resource utilization (HRU), work loss, and annual direct and indirect healthcare costs among patients with systemic sclerosis (SSc) compared to matched controls in the United States.Methods.Data were obtained from a large US commercial claims database. Patients were ≥ 18 years old at the index date (first SSc diagnosis) and had ≥ 1 SSc diagnosis in the inpatient (IP) or emergency room (ER) setting, or ≥ 2 SSc diagnoses on 2 different dates in the outpatient (OP) setting between January 1, 2005, and March 31, 2015; continuous enrollment was required during the followup period (12 months after the index date). Individuals with no SSc diagnoses were matched 1:1 to patients with SSc. Wilcoxon signed-rank and McNemar tests were used for comparisons and regressions with generalized estimating equations for adjusted OR (aOR) and incidence rate ratios (IRR) between 2 cohorts.Results.There were 2192 pairs of patients with SSc and matched controls included (mean age 57.6 yrs; 84.3% female); of these, 233 were eligible for work loss/indirect cost analyses. Compared to matched controls, patients with SSc had significantly higher HRU and costs during the 1-year followup period, IP admissions (adjusted IRR = 2.4), IP hospitalization days (adjusted IRR = 3.1), ER visits (adjusted IRR = 2.0), OP visits (adjusted IRR = 2.3), and days of work loss (adjusted IRR = 2.6). The adjusted difference in annual direct and indirect costs was US$12,820 and $3103, respectively (all p < 0.0001).Conclusion.Patients with SSc had a high direct and indirect economic burden postdiagnosis.

scholarly journals Clinical, humanistic, and economic burden of severe hemophilia B in the United States: Results from the CHESS US and CHESS US+ population surveys

2021 ◽  
Vol 16 (1) ◽  
Author(s):  
Tom Burke ◽  
Sohaib Asghar ◽  
Jamie O’Hara ◽  
Eileen K. Sawyer ◽  
Nanxin Li
Keyword(s):  
United States ◽  
Economic Burden ◽  
Indirect Costs ◽  
The United States ◽  
Factor Ix ◽  
Hemophilia B ◽  
Patient Records ◽  
Severe Hemophilia ◽  
The Us ◽  
The Mean

Abstract Background Hemophilia B is a rare congenital bleeding disorder that has a significant negative impact on patients’ functionality and health-related quality of life. The standard of care for severe hemophilia B in the United States is prophylactic factor IX replacement therapy, which incurs substantial costs for this lifelong condition. Accurate estimates of the burden of hemophilia B are important for population health management and policy decisions, but have only recently accounted for current management strategies. The ‘Cost of Severe Hemophilia across the US: a Socioeconomic Survey’ (CHESS US) is a cross-sectional database of medical record abstractions and physician-reported information, completed by hematologists and care providers. CHESS US+ is a complementary database of completed questionnaires from patients with hemophilia. Together, CHESS US and CHESS US+ provide contemporary, comprehensive information on the burden of severe hemophilia from the provider and patient perspectives. We used the CHESS US and CHESS US+ data to analyze the clinical, humanistic, and economic burden of hemophilia B for patients treated with factor IX prophylaxis between 2017 and 2019 in the US. Results We conducted analysis to assess clinical burden and direct medical costs from 44 patient records in CHESS US, and of direct non-medical costs, indirect costs, and humanistic burden (using the EQ-5D-5L) from 57 patients in CHESS US+. The mean annual bleed rate was 1.73 (standard deviation, 1.39); approximately 9% of patients experienced a bleed-related hospitalization during the 12-month study period. Nearly all patients (85%) reported chronic pain, and the mean EQ-5D-5L utility value was 0.76 (0.24). The mean annual direct medical cost was $614,886, driven by factor IX treatment (mean annual cost, $611,971). Subgroup analyses showed mean annual costs of $397,491 and $788,491 for standard and extended half-life factor IX treatment, respectively. The mean annual non-medical direct costs and indirect costs of hemophilia B were $2,371 and $6,931. Conclusions This analysis of patient records and patient-reported outcomes from CHESS US and CHESS US+ provides updated information on the considerable clinical, humanistic, and economic burden of hemophilia B in the US. Substantial unmet needs remain to improve patient care with sustainable population health strategies.

Sign in / Sign up

Export Citation Format

Share Document